Cargando…

Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol

BACKGROUND: Influenza infections often remain undiagnosed in patients admitted to hospital due to lack of routine testing. When tested for, the diagnosis and treatment of influenza are often delayed due to the slow turnaround times of centralised laboratory PCR testing. Newer molecular systems, have...

Descripción completa

Detalles Bibliográficos
Autores principales: Beard, Kate, Brendish, Nathan, Malachira, Ahalya, Mills, Samuel, Chan, Cathleen, Poole, Stephen, Clark, Tristan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937093/
https://www.ncbi.nlm.nih.gov/pubmed/31852699
http://dx.doi.org/10.1136/bmjopen-2019-031674
_version_ 1783483822310948864
author Beard, Kate
Brendish, Nathan
Malachira, Ahalya
Mills, Samuel
Chan, Cathleen
Poole, Stephen
Clark, Tristan
author_facet Beard, Kate
Brendish, Nathan
Malachira, Ahalya
Mills, Samuel
Chan, Cathleen
Poole, Stephen
Clark, Tristan
author_sort Beard, Kate
collection PubMed
description BACKGROUND: Influenza infections often remain undiagnosed in patients admitted to hospital due to lack of routine testing. When tested for, the diagnosis and treatment of influenza are often delayed due to the slow turnaround times of centralised laboratory PCR testing. Newer molecular systems, have comparable accuracy to laboratory PCR testing, and can generate a result in under 1 hour, making them potentially deployable as point-of-care tests (POCTs). High-quality evidence for the impact of routine POCT for influenza on clinical outcomes is, however, currently lacking. This large pragmatic multicentre randomised controlled trial aims to address this evidence gap. METHODS AND ANALYSIS: The FluPOC trial is a pragmatic, multicentre, randomised controlled trial evaluating adults admitted to a large teaching hospital and a district general hospital with an acute respiratory illness, during influenza season and defined by Public Health England. Up to 840 patients will be recruited over up to three influenza seasons, and randomised (1:1) to receive either POCT using the FilmArray respiratory panel, or routine clinical care. Clinical and infection control teams will be informed of the results in real time and where influenza is detected clinical teams will be encouraged to offer neuraminidase inhibitor (NAI) treatment in accordance with national guidelines. Those allocated to standard clinical care will have a swab taken for later analysis to allow assessment of missed diagnoses. The outcomes assessment will be by retrospective case note analysis. The outcome measures include the proportion of influenza-positive patients detected and appropriately treated with NAIs, isolation facility use, antibiotic use, length of hospital stay, complications and mortality. ETHICS AND DISSEMINATION: Prior to commencing the study, approval was obtained from the South Central Hampshire A Ethics Committee (reference 17/SC/0368, granted 7 September 2017). Results generated from this protocol will be published in peer-reviewed scientific journals and presented at national and international conferences. TRIAL REGISTRATION NUMBER: ISRCTN17197293
format Online
Article
Text
id pubmed-6937093
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-69370932020-01-09 Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol Beard, Kate Brendish, Nathan Malachira, Ahalya Mills, Samuel Chan, Cathleen Poole, Stephen Clark, Tristan BMJ Open Infectious Diseases BACKGROUND: Influenza infections often remain undiagnosed in patients admitted to hospital due to lack of routine testing. When tested for, the diagnosis and treatment of influenza are often delayed due to the slow turnaround times of centralised laboratory PCR testing. Newer molecular systems, have comparable accuracy to laboratory PCR testing, and can generate a result in under 1 hour, making them potentially deployable as point-of-care tests (POCTs). High-quality evidence for the impact of routine POCT for influenza on clinical outcomes is, however, currently lacking. This large pragmatic multicentre randomised controlled trial aims to address this evidence gap. METHODS AND ANALYSIS: The FluPOC trial is a pragmatic, multicentre, randomised controlled trial evaluating adults admitted to a large teaching hospital and a district general hospital with an acute respiratory illness, during influenza season and defined by Public Health England. Up to 840 patients will be recruited over up to three influenza seasons, and randomised (1:1) to receive either POCT using the FilmArray respiratory panel, or routine clinical care. Clinical and infection control teams will be informed of the results in real time and where influenza is detected clinical teams will be encouraged to offer neuraminidase inhibitor (NAI) treatment in accordance with national guidelines. Those allocated to standard clinical care will have a swab taken for later analysis to allow assessment of missed diagnoses. The outcomes assessment will be by retrospective case note analysis. The outcome measures include the proportion of influenza-positive patients detected and appropriately treated with NAIs, isolation facility use, antibiotic use, length of hospital stay, complications and mortality. ETHICS AND DISSEMINATION: Prior to commencing the study, approval was obtained from the South Central Hampshire A Ethics Committee (reference 17/SC/0368, granted 7 September 2017). Results generated from this protocol will be published in peer-reviewed scientific journals and presented at national and international conferences. TRIAL REGISTRATION NUMBER: ISRCTN17197293 BMJ Publishing Group 2019-12-17 /pmc/articles/PMC6937093/ /pubmed/31852699 http://dx.doi.org/10.1136/bmjopen-2019-031674 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Infectious Diseases
Beard, Kate
Brendish, Nathan
Malachira, Ahalya
Mills, Samuel
Chan, Cathleen
Poole, Stephen
Clark, Tristan
Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol
title Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol
title_full Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol
title_fullStr Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol
title_full_unstemmed Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol
title_short Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol
title_sort pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care ‘test-and-treat’ strategy for influenza in adults hospitalised with acute respiratory illness (flupoc): trial protocol
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937093/
https://www.ncbi.nlm.nih.gov/pubmed/31852699
http://dx.doi.org/10.1136/bmjopen-2019-031674
work_keys_str_mv AT beardkate pragmaticmulticentrerandomisedcontrolledtrialevaluatingtheimpactofaroutinemolecularpointofcaretestandtreatstrategyforinfluenzainadultshospitalisedwithacuterespiratoryillnessflupoctrialprotocol
AT brendishnathan pragmaticmulticentrerandomisedcontrolledtrialevaluatingtheimpactofaroutinemolecularpointofcaretestandtreatstrategyforinfluenzainadultshospitalisedwithacuterespiratoryillnessflupoctrialprotocol
AT malachiraahalya pragmaticmulticentrerandomisedcontrolledtrialevaluatingtheimpactofaroutinemolecularpointofcaretestandtreatstrategyforinfluenzainadultshospitalisedwithacuterespiratoryillnessflupoctrialprotocol
AT millssamuel pragmaticmulticentrerandomisedcontrolledtrialevaluatingtheimpactofaroutinemolecularpointofcaretestandtreatstrategyforinfluenzainadultshospitalisedwithacuterespiratoryillnessflupoctrialprotocol
AT chancathleen pragmaticmulticentrerandomisedcontrolledtrialevaluatingtheimpactofaroutinemolecularpointofcaretestandtreatstrategyforinfluenzainadultshospitalisedwithacuterespiratoryillnessflupoctrialprotocol
AT poolestephen pragmaticmulticentrerandomisedcontrolledtrialevaluatingtheimpactofaroutinemolecularpointofcaretestandtreatstrategyforinfluenzainadultshospitalisedwithacuterespiratoryillnessflupoctrialprotocol
AT clarktristan pragmaticmulticentrerandomisedcontrolledtrialevaluatingtheimpactofaroutinemolecularpointofcaretestandtreatstrategyforinfluenzainadultshospitalisedwithacuterespiratoryillnessflupoctrialprotocol